Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Crocs, Inc. (CROX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Crocs, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Crocs, Inc. trades at $133 (market cap $6.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6× Crocs, Inc.'s market cap, and Crocs, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CROX | |
|---|---|---|
Market Cap | $39.89B | $6.60B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $132.78 |
52-Week Low | $278.09 | $73.39 |
Enterprise Value | $38.15B | $8.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Crocs (CROX) trades at $132.78, up 4.44% with bullish technical signals and consistent earnings beats. The stock shows strong momentum above key support levels, though profitability metrics declined in 2025 with negative net income margins. Recent partnerships with LEGO and Disney are driving brand innovation and digital engagement.
Outlook remains mixed with analyst consensus favoring Buy (51%) but fundamental headwinds from margin pressure. Key risks include execution on international expansion and debt management. The stock trades near analyst target of $131.75 with upside to $150 if growth initiatives succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
